Vident Advisory’s Orchard Therapeutics plc American Depositary Shares ORTX Stock Holding History

Vident Advisory’s Portfolio ORTX Stock Details ORTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-11,270	Closed	-$185K	–	1461
2023 Q4	$185K	Buy	+11,270	New	+$177K	﹤0.01%	1232

Vident Advisory's ORTX Position: Q1 2024 in Review

Vident Advisory sold out of Orchard Therapeutics plc American Depositary Shares (ORTX) in Q1 2024, closing a stake of 11,270 shares — an estimated $185K sold.

Vident Advisory first reported a position in ORTX in Q4 2023 and held it in 1 quarter. The position peaked at $185K in Q4 2023. 0 funds tracked by Wall St. Rank hold ORTX as of Q1 2024.

Vident Advisory reported no remaining Orchard Therapeutics plc American Depositary Shares position as of Q1 2024 after selling out during the quarter.
Vident Advisory sold 11,270 Orchard Therapeutics plc American Depositary Shares shares in Q1 2024, an estimated $185K.
Vident Advisory first reported a position in Orchard Therapeutics plc American Depositary Shares in Q4 2023 and held it in 1 quarter.
Vident Advisory's Orchard Therapeutics plc American Depositary Shares position peaked at $185K in Q4 2023.
0 funds tracked by Wall St. Rank held Orchard Therapeutics plc American Depositary Shares as of Q1 2024.

Based on Vident Advisory's 13F filing for Q1 2024, filed 14 May 2024.